Что надо знать о редко встречающихся возбудителях инфекций у онкологических больных?
https://doi.org/10.18027/2224-5057-2024-14-3s1-72-79
Аннотация
Работа посвящена редко встречающимся бактериальным и грибковым возбудителям инфекций. Эти микроорганизмы создают трудности в диагностике и лечении в связи с возможными ошибками идентификации возбудителя, природной или приобретенной лекарственной резистентностью.
Возбудители редких инфекций могут колонизировать больных, образовывать биопленки, персистировать в окружающей среде, передаваться от больного к больному и приводить к развитию вспышек инфекции. Они нередко ухудшают прогноз лечения онкологического больного и приводят к летальному исходу.
Информация об особенностях редко встречающихся микроорганизмов и возможных подходах к их лечению позволит врачам-онкологам оказывать своевременную квалифицированную помощь подобным пациентам.
Об авторах
И. Н. Петухова
ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
Ирина Николаевна Петухова
115478 Москва, Каширское шоссе, 24
З. В. Григорьевская
ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
Григорьевская Злата Валерьевна
115478 Москва, Каширское шоссе, 24
Н. С. Багирова
ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Россия
Багирова Наталия Сергеевна
115478 Москва, Каширское шоссе, 24
125993 Москва, ул. Баррикадная, 2 / 1, стр. 1
В. В. Агинова
ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
Агинова Виктория Викторовна
115478 Москва, Каширское шоссе, 24
Список литературы
1. Mobedi I., Daee-Ghazvini F., Nakhjavani F.A., et al. Actinomyces naeslundii patients with hematological malignancies. Acta Medica Iranica 2006;44(5):345–348.
2. Pierre I., Zarrouk V., Noussar L., et al. . Invasive actinomycosis: a surrogate marker of a poor prognosis in immunocompromised patients. Int J Infect Dis 2014;29:74–79. https://doi.org/10.1016/j.ijid.2014.06.012
3. Dos Santos Menezes A.C., Daltro Borges Alves L., de Assis Ramos G., et al. The multiple presentation of oral actinomycosis in post-hematopoietic stem cell transplantation patients: case series. Hematol Transfus Cell Ther 2023:1–7. https://doi.org/10.1016/j.htct.2023.11.003
4. Бурова С.А. Актиномикоз. РМЖ 2001;3:146–148
5. Чернеховская Н.Е., Бурова С.А., Поваляев А.В. Актиномикоз бронхов и легких. Пульмонология 2008;3:107–109. https://doi.org/10.18093/0869-0189-2008-0-3-107-109
6. Torres H.A., Reddy B.T., Raad I.I., et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002;81(5):388–97. https://doi.org/10.1097/00005792-200209000-00004
7. Lopes K., Montenegro C., Vilchez J., et al. IMAGES: Nocardia pneumonia – A surprising and rare pulmonary infection mimicking lung cancer. Pulmonology 2022;28(5):415–417. https://doi.org/10.1016/j.pulmoe.2022.03.013
8. Kao H., Tsai C.A., Sun M.H., et al. Nocardia brain abscess in a patient of lung cancer. Int J Clin Med Imaging 2016;3(10):512. https://doi.org/10.4172/2376-0249.1000512
9. Petitgas P., Lesouhaitier M., Boukthir S., et al. Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report. BMC Infect Dis 2022;22:306. https://doi.org/10.1186/s12879-022-07288-4
10. Lee E.K., Kim J., Park D.H., et al. Disseminated nocardiosis caused by Nocardia farcinica in a patient with colon cancer. A case report and literature review. Medicine 2021;100:29(e26682). https://doi.org/10.1097/MD.0000000000026682
11. Yang M., Xu M., Wei W., et al. Clinical findings of 40 patients with nocardiosis: A retrospective analysis in a tertiary hospital. Exp Ther Med 2014;8(1):25–30. https://doi.org/10.3892/etm.2014.1715
12. Al Akhrass F., Hachen R., Mohamed J.A., et al. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis 2011;17(9):1651. https://doi.org/103201/eid1709.101810
13. Cattaneo C., Antoniazzi F., Caira M., et al. Nocardia spp. infections among hematological patients: results of a retrospective multicenter study. Int J Infect Dis 2013:17:e610-e614. https://doi.org/10.1016/j.ijid.2013.01.013
14. Miyaoka C., Nakamoto K., Shirai T., et al. Pulmonary nocardiosis caused by Nocardia exalbida mimickimg lung cancer. Respirology Case Reports 2019;7(7):e00458. https://doi.org/10.1002/rcr2.458
15. Ansari S.R., Safdar A., Han X.Y., O`Brien S. Nocardia veterana bloodstream infection in a patient with cancer and a summary of reported cases. Int J Infect Dis 2006;10(6):483–6. https://doi.org/10.1016/j.ijid.2006.03.005
16. Kmeid J., Kulkarni P.A., Batista M.V., et al. Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006–2014. BMC Infect Dis 2019;19(1):934. https://doi.org/10.1186/s12879-019-4586-y
17. Комиссарова О., Михайловский А., Абдуллаев Р. Туберкулез легких и злокачественные новообразования. Врач 2020;2:3–6. https://doi.org/10.29296/25877305-2020-02-01
18. Kamboj M., Sepkowitz K.A. The risk of tuberculosis in patients with cancer. Clin Infect Dis 200. 6;42(11):1592–5. https://doi.org/10.1086/503917
19. Dobler C.C., Cheung K., Nguen J., Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J 2017;50(2):1700157. https://doi.org/10.1183/13993003.00157-2017
20. Siewchaisakul P., Nanthanangkul S., Santong C., et al. Survival of cancer patients with co-morbid tuberculosis in Thailand. Asian Pac J Cancer Prev 2021;22(8):2701–2708. https://doi.org/10.31557/APJCP.2021.22.8.2701
21. Kato Y., Watanabe Y., Yamane Y., et al. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report. Immunotherapy 2020;12(6):373–378. https://doi.org/10.2217/imt-2020-0061
22. Anastasopoulou A., Ziogas D.C., Samarkos M., et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer 2019;7(1):239–251. https://doi,org/10.1186/s40425-019-0717-7
23. Hirashima T., Tamura Y., Hashimoto S., et al. Efficacy and safety of concurrent anti-cancer and anti-tuberculosis chemotherapy in cancer patients with active Mycobacterium tuberculosis: a retrospective study. BMC Cancer 2018;18(1):975–984. https://doi.org/10.1186/s12885-018-4889-1
24. Tadmori I., Benmiloud S., Habibi M., Hida M. Active tuberculosis in children receiving chemotherapy. Open Journal of Pediatrics 2022;12(1);75–78. https://doi.org/10.4236/ojped.2022.121009
25. Aldabbah M.A., Abughasham A., Alansari G.A., et al. The prevalence of Mycobacterium tuberculosis infection among cancer patients, receiving chemotherapy in a tertiary care center. Cureus 2022;14(11):e32068. https://doi.org/10.7759/cureus.32068
26. Pennington K.M., Vu A., Ghallener D., et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tub Other Mycobact Dis 2021;24:100244. https://doi.org/10.1016/j.jctube.2021.100244
27. Addisu A., Alok A., Binkam M., et al. Nontuberculous Mycobacterial isolates among cancer patients: A single-center 5-year experience. Infect Dis Clin Practice 2023;31(1):e1195. https://doi.org/10.1097/IPC.0000000000001195
28. Al-Anazi K.A., Al-Jasser A.M., Al-Anazi W.K. Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation. Front Oncol 2014;4:311. https://doi.org/10.3389/fonc.2014.00311
29. Redelman-Sidi G., Sepkowitz K.A. Rapidly growing mycobacteria infection in patients with cancer. Clin Infect Dis 2010;51(4):422–434. https://doi.org/10.1086/655140
30. Yoon H.J., Choi H.Y., Ki M. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea. BMC Infect Dis 2017;17(1):432. https://doi.org/10.1186/s12879-017-2532-4
31. Da Costa A.R.F., Falkinham J.O. 3rd, Lopez M.L., et al. Occurrence of nontuberculosis mycobacterial pulmonary infection in an endemic area of tuberculosis. PLoS Negl Trop Dis 2013;7(7):e2340. https://doi.org/10.1371/journal.pntd.0002340
32. Goswami P.N., Kishore A. Infections with yeast and yeast like fungi in cancer patients with special emphasis on non-neoformans cryptococcal infections: Retrospective study. Indian J Microbiol Res 2019;6(3):213–220. https://doi.org/10.18231/j.ijmr.2019.047
33. Patel V., Desjardins M., Cowan J. Shift in epidemiology of Cryptococcal infections in Ottawa with high-mortality in Non-HIV immunocompromised patients. J Fungi 2019;5(4):104. https://doi.org/10.3390/jof5040104
34. Coussement J., Heath C.H., Roberts M.B., et al. Current epidemiology and clinical features of Cryptococcus infection in patients without human immunodeficiency virus: a multicenter study in 46 hospitals in Australia and New Zealand. Clin Infect Dis 2023;77(7):976–86. https://doi.org/10.1093/cid/ciad321
35. Kontoyiannis D.P., Peitsch W.K., Reddy B.T., et al. Cryptococcosis in patients with cancer. Clin Infect Dis 2001;32(11):е145–50. https://doi.org/10.1086/320524
36. Gangadharan S.S., Raveendranath S. Cryptococcosis in oncology patients: a case series in a tertiary care cancer centre. Iran J Microbiol 2023;15(6):821–825. https://doi.org/10.18502/ijm.v15i6.14163
37. Liu K., Ding H., Xu B., et al. Clinical analysis of non-AIDS patients pathologically diagnosed with pulmonary cryptococcosis, J Thorac Dis 2016;8(10):2813–2821. https://doi.org/10.21037/jtd.2016.10.36
38. Li H., Guo M., Wang C., et al. Epidemiological study of Trichosporon asahii infections over the past 23 years. Epidemiol Infect 2020;148:e169. https://doi.org/10.1017/S0950268820001624
39. Mehta V., Nayyar C., Gulati N., et al. A comprehensive review of Trichosporon spp.: An Invasive and Emerging Fungus. Cureus 2021;13(8):e17345. https://doi.org/10.77/cureus.17345
40. Montoya A.M., Gonzalez G.M. Trichosporon spp.: an emerging fungal pathogen. Medicina Universitaria 2014:16(62):37–43
41. Abbas A.A., Alamri A.W., Almofti A.H. Trichosporon asahii infection mortality in pediatric oncology patients: a report of six patients. J Microbiol Infect Dis 2020;10(3):167–172. https://doi.org/10.5799/jmid.790293
42. Robles-Tenorio A., Rivas-Lopez R.A., Bonifaz A., Tarango-Martinez V.M. Disseminated mucocutaneous trichosporonosis in a patient with histiocytic sarcoma. An Bras Dermatol 2021;96(5):595–597. https://doi.org/10.1016/j.abd.2021.01.003
43. Байбак О.И., Абугова Ю.Г., Пирумова Р.П. и соавт. Инвазивный микоз, вызванный Trichosporon mucoides. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2017;16(1):49–53. https://doi.org/10.24287/1726-1708-2017-16-1-49-53
44. El Omri H., Fathallah-Mili A., Ben Youssef Y., et al. Geotrichum capitatum septicemia in neutropenic patient, case report and review. Journal de Mycologie Medicale 2005;15(4):242–246. https://doi.org/10.1016/j.mycmed.2005.09.002
45. Gao G.X., Tang H.L., Zhang X., et al. Invasive fungal infection caused by Geotrichum capitatum in patients with acute lymphoblastic leukemia: a case study and literature review. Int J Clin Exp Med 2015;8(8):14228–14235.
46. Sulik-Tyszka B., Snarski E., Niedzwiedzka M., et al. Experience of Saccharomyces boulardii probiotic in oncohaematological patients. Probiotics & Antimicro Prot 2018;10(2):350–355. https://doi.org/10.1007/s12602-017-9332-4
47. Enache-Angoulvant A., Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41(11):1559–68. https://doi.org/10.1086/497832
48. Chakravarty S., Parashar A., Acharyya S. Saccharomyces cerevisiae sepsis following probiotic therapy in an infant. Indian Pediatr 2019;56(11):971–972
49. Батманова Н.А., Багирова Н.С., Григорьевская З.В. и соавт. Успешная диагностика и лечение фузариоза у больной острым лейкозом. Гематология и трансфузиология 2022;67(1):139–149. https://doi.org/10.35754/0234-5730-2022-67-1-139-149
50. Nucci M., Anassie E.J., Queiros-Telles F., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98(2):315–319. https://doi.org/10.1002/cncr.11510
51. Hoyos-Pulgarin J.A., Arias-Ramos D., Gonzalez-Diaz J.A., Ramirez N.M. Unusual finding in Gram staining of blood cultures in a patient with prolonged febrile neutropenia and acute myeloid leukemia. Enferm Infecc Microbiol Clin 2020;38(7):338–340. https://doi.org/10.1016/j.eimc.2019.12.015
52. Hayashida M.Z., Seque C.A., Simoes e Silva Enokihara M.M., Porro A.M. Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate. An Bras Dermatol 2018;93(5):726–9. https://doi.org/10.1590/abd1806-4841.20187476
53. Liu Y.S., Wang N.C., Ye R.H., Kao W.Y. Disseminated Fusarium infection in a patient with acute lymphoblastic leukemia: a case report and review of the literature. Oncol Lett 2014;7(2):334–336. https://doi.org/10.3892.ol.2013.1738
54. Tortorano A.M., Prigetano A., Esposto M.C., et al. European Medical Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis 2014;33(9):1623–30. https://doi.org/10.1007/s10096-014-2111-1
55. Ferreira Chagas D., Martins Diniz L., Almeida Lucas E., Emerich Noguera P.S. Disseminated fusariosis in a patient with bone marrow aplasia. An Bras Dermatol 2020;95(5):609–614. https://doi.org/10.1016/j.abd.2019.12.008
56. Marinovic D.A., Bhaimia E., Forrest G.N., et al. Scedosporium infection disseminated “from toe to head ” in allogeneic stem cell transplant recipient: a case report. BMC Infect Dis 2023;23(1):353. https://doi.org/10.1186/s12879-023-08345-2
57. Seidel D., Meissner A., Lackner M., et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and Fungiscope®. Crit Rev Microbiol 2019;45(1):1–21. https://doi.org/10.1080/1040841X.2018.1514
58. Goldman C., Akiyama M.J., Torres J., et al. Scedosporium apiospermum and the role of combination antifungal therapy and GM-CSF: a case report and review of the literature. Med Mycol Case Rep 2016;11:40–43. https://doi.org/j.mmcr.2016.04.005
59. Woolhouse M.E. Population biology of emerging and reemerging pathogens. Trends Microbiol 2002;10(10, Suppl.):S3-S7. https://doi.org/10.1016/s0966-842x(02)02428-9.
Рецензия
Для цитирования:
Петухова И.Н., Григорьевская З.В., Багирова Н.С., Агинова В.В. Что надо знать о редко встречающихся возбудителях инфекций у онкологических больных? Злокачественные опухоли. 2024;14(3s1):72-79. https://doi.org/10.18027/2224-5057-2024-14-3s1-72-79
Просмотров:
141
Послать статью по эл. почте 